Melanoma-associated antigen family (typically refers to the MAGE-A subfamily, such as "Melanoma-associated antigen 1" for MAGEA1) (MAGE-A (or specific members, e.g., MAGEA1, MAGEA3, etc.))

Melanoma-associated antigen A (MAGE-A) refers to a subfamily of cancer/testis antigens originally discovered in melanoma and subsequently found to be expressed in a variety of human cancers but largely silent in normal adult tissues except for testis and placenta. MAGE-A genes encode intracellular proteins that share a conserved domain and often function as T-cell recognition antigens or modulators of ubiquitin ligase activity. Expression of MAGE-A proteins in tumors provides opportunities for their use as diagnostic/prognostic biomarkers and as targets for immunotherapeutic approaches, including peptide vaccines and adoptive T-cell therapies. Overexpression of MAGE-A proteins is generally associated with poor prognosis in multiple cancers due to roles in cancer progression, metastasis, and recurrence. Notable members include MAGEA1, MAGEA3, and others, each with some tissue and cancer specificity. Safety considerations for targeting MAGE-A include the risk of off-target effects in normal tissues expressing these antigens and the heterogeneous pattern of expression across tumor cells.

Other names

MAGE-AMelanoma-associated antigen AMAGEACancer/testis antigen (for the broader class)Melanoma antigen recognized by T cells 1 (MART-1; for MLANA, distinct but often conflated in cancer context)

Immune checkpoint activation or adoptive cellular therapy (T-cell mediated tumor targeting of MAGE-A expressing cells) Cancer vaccine (induction of T-cell immunity using MAGE-A peptides)